Ralliant (NYSE:RAL) SVP Karen Bick Sells 6,062 Shares

Ralliant Corporation (NYSE:RAL) SVP Karen Bick sold 6,062 shares of Ralliant stock in a transaction on Monday, August 17th. The stock was sold at an average price of $72.00, for a total transaction of $436,464.00. Following the completion of the transaction, the senior vice president directly owned 31,668 shares in the company, valued at approximately $2,280,096. The trade was a 16.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ralliant Trading Down 3.5%

NYSE:RAL opened at $69.42 on Wednesday. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.75. The company has a fifty day moving average of $68.94 and a 200 day moving average of $55.70. The firm has a market capitalization of $7.68 billion, a P/E ratio of -6.40, a P/E/G ratio of 2.69 and a beta of 1.61. Ralliant Corporation has a 52 week low of $37.27 and a 52 week high of $75.41.

Ralliant (NYSE:RAL) last posted its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The company had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, research analysts predict that Ralliant Corporation will post 2.87 earnings per share for the current year.

Ralliant Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 8th. Ralliant’s dividend payout ratio (DPR) is currently -1.84%.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RAL. Dunhill Financial LLC bought a new stake in shares of Ralliant during the second quarter valued at approximately $25,000. Global Retirement Partners LLC purchased a new stake in Ralliant in the second quarter worth $35,000. Group One Trading LLC bought a new position in Ralliant in the second quarter worth $36,000. Danske Bank A S purchased a new position in Ralliant during the fourth quarter valued at $25,000. Finally, Persistent Asset Partners Ltd purchased a new position in Ralliant during the second quarter valued at $37,000.

Analysts Set New Price Targets

A number of brokerages recently commented on RAL. Wall Street Zen downgraded Ralliant from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 11th. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a report on Friday, July 31st. Citigroup upped their price objective on shares of Ralliant from $81.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, July 31st. TD Cowen raised their target price on shares of Ralliant from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Barclays lifted their target price on shares of Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Ralliant currently has an average rating of “Moderate Buy” and a consensus target price of $75.70.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.